ArticleEuropean journal of clinical pharmacology2026
Clozapine and Mirabegron, a case report of drug-drug interaction with severe consequences in a geriatric patient.
Article in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare but clinically significant drug-drug interaction between clozapine and mirabegron in a 63-year-old man with schizophrenia. The patient presented with repeated falls, drowsiness and balance disorders following initiation of mirabegron for overactive bladder. Clozapine plasma levels progressively exceeded the therapeutic range. Dose reduction of clozapine restored concentrations to target levels and improved mobility and alertness, with only one fall reported after adjustment. This case highlights a probable pharmacokinetic interaction through mirabegron's moderate inhibition of CYP2D6, contributing to clozapine overdose. Only one similar case has previously been published. Clinicians should be aware of this interaction, especially in older patients with polypharmacy. Monitoring clozapine concentrations after introduction of clozapine's cytochrome inhibitors is recommended to prevent dose-dependent adverse effects such as sedation and falls, particularly in vulnerable populations such as older patients.
Indexed as
Identifiers
41553535What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.